ArticleScientific reports2025
Development, validation, and updating of prognostic models for m7G-associated genes from TAMs in lower-grade gliomas.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
As the crucial component of the glioma microenvironment, tumor-associated macrophages (TAMs) significantly contribute to the immunosuppressive microenvironment and strongly influence glioma progression via various signaling molecules, simultaneously providing new insight into therapeutic strategies. Studies are aiming at developing prognostic models using N7-methylguanosine (m7G)-related genes in gliomas, however, models with good predictive performance for lower-grade gliomas have yet to be developed. Based on genes with m7G variants and clinical information, two prediction models have been derived to predict the probability of survival for patients with lower-grade gliomas in TCGA. The models were externally validated using independent datasets. Based on CGGA information, updated models that were created matched the features of the local population. Two models were derived, validated and updated. Model 1, which was derived on the basis of mRNA, only contains five genes: CD37, EIF3A, CALU, COLGALT1, and DDX3X. Model 2 included six variables: grade, age, gender, IDH mutation status, 1p/19q codeletion status and prognostic index of model 1. The C-statistic of revised model 1 was 0.764 (95% CI 0.730-0.798) in the revised set and 0.700 (95% CI 0.658-0.742) in the test set. Regarding internal validation, C-statistic for model 2 with 1000 bootstrap replications was 0.848, while in external validation, the C-statistic was 0.752 (95% CI 0.714-0.788). Both models exhibited satisfactory calibration after updating in external validation. The models' web calculator is provided at https://lhj0520.shinyapps.io/M7G-LGG_model/ .
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.